About our project

The problem we solve: 1. Patients with chronic conditions can see their clinicians only couple times a year for regularly scheduled visits and while dealing with heavy medication and complications, they cannot track their symptoms accurately. 2. Care teams have limited time to assess the progression of chronic pain during visits, rely on paper forms and assessments which are in text form with no quantitative data. 3. Payors and Providers are seeking meaningful and realtime chronic disease data to deliver value-based care which translates to significant cost savings.

About our solution: The mobile applications technology developed by cliexa™ enables patients to track their chronic disease activity by quantifying symptoms with scientifically-proven and clinically-validated scoring models along with tracking the details of the medication and care plan and integrate the patient collected data into EHR systems. Value proposition and Innovation: • cliexa provides maximum user experience and best outcomes for patients which translates to better quality of life. • cliexa provides clinicians time and ability to deliver value-based care which translates to significant cost savings. • cliexa delivers meaningful data with quantified disease activity and medication adherence through patient reported outcomes for payors which streamlines processes and increases efficiency in population health management. • cliexa provides pharma companies and research organizations data to get regulatory clearance and approval, can improve the quality and reduce the costs of clinical trials.

CURRENT PILOTS:

• cliexa-RA: Kaiser Permanente Rock Creek Rheumatology Clinic since November 2016
• cliexa-RA Digital Forms: Colorado Arthritis Center since August 2017
• cliexa-Ease Pain Management: CU Boulder Neuroscience Department since November 2017
• cliexa-Ease Pain Management: Colorado Comprehensive Spinal Institute since November 2017
• cliexa-Options Behavioral Health: UCHealth Longmont Clinic since January 2017

TRACTION:

• FDA 513g Clearance Received for Evidence-Based Data Indexing on May 2016
• cliexa-RA featured in NIH Article as one of the top 19 apps among 936 reviewed - February 2017
• License Agreement with Ted Pincus, MD for cliexa-RA Rapid 3 Model 
• Selected as Alpha Startup to present at Collision Conference - May 2017
• Selected G-Startup Worldwide Silicon Valley Top 50 Startups - July 2017
• Became Epic AppOrchard Approved Vendor of 140 companies - August 2017
• Won Village Capital Peer Review Award 1st Place by Venture Hall - September 2017
• cliexa Trademark is registered - September 2017
• CU Boulder Neuroscience Dept. Partnership - November 2017
• Preventative Technology Solutions Partnership for behavioral health - December 2017

Two patents filed:

• Disease Management Protocols and Evidence-Based Data Indexing Patent-Pending since May 2015
• Multidimensional Pain Tracking Provisional Patent Filed jointly with CU Boulder Neuroscience Department - January 2018

About Our Company

How We Help Patients

cliexa provides patients maximum experience and best outcomes which translates into better quality of life. It improves their quality of life through our superior interactive mobile experience. cliexa's engagement, functionality, aesthetics and reported outcomes collected through the mobile platform gives patients empowerment over their chronic disease management for improved care.

How We Help Physicians

cliexa enables providers time and ability to deliver value-based care which translates to significant cost savings.

Data + Process + Output → Behavior change

The cliexa-Protocols disease management algorithms (patent pending) enable clinicians to have a more holistic view on the pain their patients are experiencing. These algorithms also assist providers in making more informed decisions about treatment plans, and enable them to respond more quickly to new data so their patients will have fewer complications or side effects.

Unlike existing solutions, cliexa uses multiple scoring models to provide clinicians multiple reference points with correlations to identify the accuracy of patient reported data which will result in better patient and clinician experience and enables more responsive and preventive treatment.

How We Help Hospitals

cliexa suite of products enables providers such as private clinics, hospitals time and ability to deliver value-based care which translates to significant cost savings. Unlike existing solutions, cliexa uses multiple scoring models to provide clinicians multiple reference points with correlations to identify the accuracy of patient reported data which will result in better patient and clinician experience and enables more responsive and preventive treatment.

How We Help Partners

Value Proposition: preventative and responsive approach to care and having regular access to chronic care analytics.

Patient reported outcomes + medication adherence = comprehensive data for improved care

The suite of products which cliexa offers health insurance companies combines chronic care analytics with evidence-based data to optimize treatment models and reduce medical expenses from 10% to 30%. cliexa documents improved outcomes, provides chronic care analytics which streamlines quality focused processes. cliexa delivers meaningful data with quantified disease activity and medication adherence through patient reported outcomes which streamlines processes and increases efficiency in population health management.

Research Organizations and Pharma Companies

Value proposition: Provide data to get regulatory clearance and approval

cliexa provides data to get regulatory clearance and approval, can improve the quality and reduce the costs of clinical trials.

Product Partners

Value Proposition: ability to track patients with additional chronic disease markers collected through patient reported outcomes

cliexa provides meaningful data to teams who touches the patient along the "care pathway" can use this info.

cliexa partners with medical device and service providers and feed additional chronic disease markers collected through patient reported outcomes for more responsive and efficient services which translates to better outcomes.

Challenge Mission

Innovation Details

Intellectual Property Summary

1. Disease Management Protocols and Evidence-Based Data Indexing Patent-Pending since May 2015
2. Multidimensional Pain Tracking Provisional Patent Filed jointly with CU Boulder Neuroscience Department - January 2018

Clinical Information

1. Managing chronic conditions by closing the feedback loop between the patients and clinicians can save 30-60%. 

   Sutter Health. Nine of 10 sites reporting; Q2 2013-Q1 2014; n-1544/ Project is supported by grant number 1C1CMS331005-01-00 from Centers for Medicare & Medicaid Services, Center for Medicare and Medicaid Innovation

   Return on Investment in Disease Management (2005): A Review, Ron Z. Goetzel, PhD, Ronald J Ozminkowski PhD, Victor G Villagra, MD, Jennifer Duffy

2. cliexa-RA has been featured as one of the top 19 apps selected among 936 Rheumatoid Arthritis apps according to an NIH article published in February 2017 and is the only app that has, validated disease activity calculations, data tracking tools, 28 tender and swollen joint counts and remote patient-care team engagement. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340922/

3. Patients with age of 60-65 show no different in their adoption rate for portal accounts when compared to patients with age of 30-50. https://hbr.org/2015/06/using-data-to-increase-patient-engagement-in-health-care
4. About 93% of physicians feel mHealth apps can boost a patient’s healthcare outcome. 89% of physicians said they would likely recommend an mHealth app to their patients. https://www.eclinicalworks.com/pr-eclinicalworks-invests-25-million/
5. Almost two-thirds of physicians rank medication adherence as a key health concern that could be remedied by an mHealth app linked to a patient’s EHR, while more than half said diabetes (54%) and preventative care (52%) http://www.chcf.org/~/media/MEDIA%20LIBRARY%20Files/PDF/PDF%20M/PDF%20MeasuringImpactPatientPortals.pdf

Regulatory Status

We have received our clearance from FDA for our 513g application on May 2016.

How we will use the funds raised

Sales & Marketing:

• B2C and B2B Sales & Marketing Campaigns
• Hiring Sales Resources

EMR Integration:

• Epic AppOrchard App Development
• HL7 and FIHR APIs for all EMR systems

Product Development

• Security Audit and Interoperability Enhancements (HITRUST)
• Behavior Health
• Oncology
• Diabetes
• Cystic Fibrosis
• AFib
• Multiple Sclerosis

Thank You

cliexa's most important mission is to give better quality of life to chronic disease patients.

Investor Info

Market Size

Chronic diseases and their treatment overwhelm the healthcare ecosystem in the United States, with 117 Million sufferers and spending near $1.1 trillion annually (or 40% of US healthcare costs), radical changes must be made to make a foreseeable impact on the problem at hand.1 Experts agree that the core of this problem is not the advancement of biomedical research and/or medicine, but changes in the approach and behavior of patients combined with the necessary tools to relay pertinent and consistent data points to their healthcare providers during the ongoing course of their illness along with the ability to translate large data sets into meaningful information.2 

Often, patients have difficulty tracking their chronic disease activity and medication history, which compounds issues that arise from limited time with their providers to communicate the status of their chronic pain. Similarly, providers have limited time and data to holistically assess the progression of chronic pain and make treatment modifications.

1.     National Medical Expenditures Panel Survey of 2012 (MEPS). https://meps.ahrq.gov/mepsweb/index.jsp

2.     Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 Update. Prev Chronic Dis. 2014;11:130389. DOI: http://dx.doi.org/10.5888/pcd11.130389

Projected 3 Year Growth

cliexa plans to manage at least 10,000 chronic disease patients with its platform and reach up to $7 MM yearly revenue.

Revenue Model

cliexa has 3 different product lines for each disease state (Rheumatoid Arthritis, Fybromyalgia, Pain Assessment, Sexual Risk Assessment, Drug and Alcohol Abuse Assessment, Mental Health Assessment)

1. Clinic Disease Assessment: Digital Forms with standard and custom assessment models, fully reimbursable by CPT codes. ($10/assessment)
2. Remote Patient Monitoring:Suite of mobile apps with advanced features and data analytics reporting services with integration to EMR systems. ($10/patient/ymonth)

Competitors

Our closest competitors are Optum, AtPointofCare, Self Care Catalysts from chronic care management perspective and they are highly focused on patient compliance or patient engagement. For assessments, majority of the subspecialty clinics currently use paper forms and remote patient follow and monitoring is handled by phone calls. There are 936 Rheumatoid Arthritis apps in app stores alone.

cliexa's mission is to close the feedback loop with the patients and care teams with a platform that speaks both side's languages and collect meaningful chronic disease activity data. This not only handles patient compliance and engagement but highly supports the population health management by adding behavioral health components. cliexa's agility of assessment customization, partnerships with EMR systems also make it unique in the market to engage rapidly and scale. We would like to be the Optum for Kaiser Permanente and other big institutions. Please also refer to the pitch deck about NIH article published for Rheumatoid Arthritis Apps review where cliexa was one of the top 19 apps featured and #1 with multiple features being offered.

According to recent NIH article (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340922/) "Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality" (February 2017), cliexa-RA mobile application for Rheumatoid Arthritis has been featured in top 19 apps among 936 apps reviewed.

Traction

• cliexa launched cliexa-RA for Rheumatoid Arthritis and cliexa-IBD for Crohn's Disease for both iOS and Android platforms in January 2016.
• By December 2016, cliexa launched cliexa-OPD for COPD exclusively for Kaiser Permanente.
• cliexa received its 513g clearance from FDA for disease management protocols in May 2016.
• In May 2016, cliexa was selected and developed first in its class through the Boomtown Health Accelerator program and partnered with Kaiser Permanente Rheumatology Group in Colorado for a pilot in November 2016.
• Raised Seed funding of $350,000 in January 2017.
• NIH research that was published in February 2017 listed cliexa-RA as one of the top 19 mobile RA Apps among 936 RA apps, which solidified cliexa-RA’s product development success. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340922/).
• cliexa partnered with Dr. Ted Pincus, Rheumatologist and inventor of Rapid 3 and MDHAQ models in May 2017 and licensed those 2 models for cliexa-RA. Dr. Ted Pincus joined as a clinical advisor to cliexa.
• cliexa launched cliexa-MOD, tablet version of digitized forms for clinics and started a pilot at Colorado Arthritis Clinic on August 2017.
• Graduated from Venture Hall Accelerator Program on September 2017 and won the 1st Place Peer Review Grant of $25,000.
• Engaged with Maine Health for cliexa-CHF and cliexa-COPD for piloting the mobile platforms for Congestive Heart Failure and Chronic Obstructive Pulmonary Disease
• Selected as Alpha Startup to present at Collision Conference - May 2017
• Selected G-Startup Worldwide Silicon Valley Top 50 Startups - July 2017
• Became Epic AppOrchard Approved Vendor of 140 companies - August 2017
• cliexa Trademark is registered - September 2017
• Partnered with CU Boulder Neuroscience Dept for Multidimensional Pain Tracking Research and launched beta version for cliexa-Ease which is currently being utilized for pain tracking with patients with back pain - November 2017
• Partnered with Preventative Technology Solutions for exclusive behavioral health assessment models which is now available only at cliexa-Options- December 2017

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.

Send access request

Supporters

• 
  Dr Norman Goldwasser
  05/07/2019 - Liked the project.
• 
  Mr. Mehmet Kazgan, Master of Science
  01/18/2018 - Liked the project.

Comments

Updates

No updates found .